Literature DB >> 15206720

Expression of indoleamine 2,3-dioxygenase in carcinoma of human endometrium and uterine cervix.

Peter Sedlmayr1, Michaela Semlitsch, Girmai Gebru, Eva Karpf, Olaf Reich, Tao Tang, Reinhold Wintersteiger, Osamu Takikawa, Gottfried Dohr.   

Abstract

Expression of indoleamine 2,3-dioxygenase (IDO) in epithelium of the endometrium and the cervix is not restricted to normal but also present in carcinomatous tissue. The enzyme was found in the majority of cases studied, pioneer cells at the invasion front of the tumors being especially strongly reactive in immunohistology. In addition, also cells in the peritumoral infiltrate of the stroma expressed IDO. Taken together, these findings together with previous data on the immunosuppressive impact of tryptophan depletion suggest IDO-induced suppression of antitumoral immune response in both adenocarcinoma and squamous cell carcinoma of endometrium and cervix. On the other hand, IDO as also known to inhibit tumor cell proliferation by tryptophan depletion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15206720     DOI: 10.1007/978-1-4615-0135-0_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

Review 1.  Challenges and future perspectives of T cell immunotherapy in cancer.

Authors:  Maria Teresa P de Aquino; Anshu Malhotra; Manoj K Mishra; Anil Shanker
Journal:  Immunol Lett       Date:  2015-06-19       Impact factor: 3.685

2.  Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas.

Authors:  Jinzhong Liu; Gaofeng Lu; Fuai Tang; Yiqing Liu; Guanglin Cui
Journal:  Virchows Arch       Date:  2009-10-21       Impact factor: 4.064

3.  Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer.

Authors:  K Ino; N Yoshida; H Kajiyama; K Shibata; E Yamamoto; K Kidokoro; N Takahashi; M Terauchi; A Nawa; S Nomura; T Nagasaka; O Takikawa; F Kikkawa
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640

4.  Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.

Authors:  Anke Vanderstraeten; Catherine Luyten; Godelieve Verbist; Sandra Tuyaerts; Frederic Amant
Journal:  Cancer Immunol Immunother       Date:  2014-06       Impact factor: 6.968

Review 5.  Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors.

Authors:  Bilal Zulfiqar; Amnah Mahroo; Kaenat Nasir; Rai Khalid Farooq; Nasir Jalal; Muhammad Usman Rashid; Kashif Asghar
Journal:  Onco Targets Ther       Date:  2017-01-21       Impact factor: 4.147

6.  The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer.

Authors:  Yan-Fang Gao; Rui-Qing Peng; Jiang Li; Ya Ding; Xing Zhang; Xiao-Jun Wu; Zhi-Zhong Pan; De-Sen Wan; Yi-Xin Zeng; Xiao-Shi Zhang
Journal:  J Transl Med       Date:  2009-08-20       Impact factor: 5.531

7.  Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions.

Authors:  Trinidad Garcia-Iglesias; Alicia Del Toro-Arreola; Benibelks Albarran-Somoza; Susana Del Toro-Arreola; Pedro E Sanchez-Hernandez; Maria Guadalupe Ramirez-Dueñas; Luz Ma Adriana Balderas-Peña; Alejandro Bravo-Cuellar; Pablo C Ortiz-Lazareno; Adrian Daneri-Navarro
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.